Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Chief Financial Officer | March 15, 2024 | March 19, 2024 |
| NEUROPATHIX, INC.NPTX · Entity 126275 | Director | March 12, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2034-03-01 | Direct | 3,475,000 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 53,500 · Balance 3,475,000 F1: Reporting Person acquired a Convertible Note face $53,500. The Note is convertible into shares of the Issuers common stock at a price of $0.02 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person acquired a Convertible Note face $53,500. The Note is convertible into shares of the Issuers common stock at a price of $0.02 per share.
NEUROPATHIX, INC.
Report date March 12, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2031-03-11 | Direct | 600,000 |
Reported balance
After 2021-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-12 · Grant · Acquired 600,000 · Balance 600,000 F1: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 19:16 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 53,500 | $53,500.00 Strike: $0.02 | $2,862,250,000.00 |
DisclosureSEC source: 0001096906-24-000511 · form4.xml · derivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475,000 Underlying: Common Stock · 2,675,000 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a Convertible Note face $53,500. The Note is convertible into shares of the Issuers common stock at a price of $0.02 per share. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 16:33 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 500,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001096906-22-002337 · form4.xml · derivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 500,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: Reporting Person acquired an option to purchase up to 500,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 17:02 UTC | NEUROPATHIX, INC. NPTX · Entity 126275 | GrantEmployee Stock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001607062-21-000054 · primary_doc.xml · derivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter. Read SEC document |
| December 10, 2020 Filed Sep 23, 2022 16:31 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 300,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001096906-22-002336 · form4.xml · derivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-12-10 Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:43 UTC | NEUROPATHIX, INC. KLFE · Entity 126275 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001683168-20-001429 · ownership.xml · derivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-05-03 F1 · derivative.exercise_date: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months commencing with the vesting commencement date of January 1, 2020. Read SEC document |
| August 14, 2019 Filed May 6, 2020 21:38 UTC | NEUROPATHIX, INC. KLFE · Entity 126275 | GrantCommon Stock | 250,000 | $0.10 | $25,000.00 |
DisclosureSEC source: 0001683168-20-001423 · ownership.xml · nonDerivative · entry 1 MALASEK ROBERT · CIK 0001493185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
| March 21, 2018 Filed Apr 6, 2018 15:35 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-18-000415 · primary_doc.xml · nonDerivative · entry 1 MALASEK ROBERT · CIK 0001493185 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.